Catalysts · ARGX · CIK 1697862 · page 2 of 2

ARGX catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on ARGX PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
August 25, 2025—ARGXTopline readout—PositiveSEC 8-K Exhibit 99.1
July 2, 2025efgartigimod ivARGXPrimary completionLupus NephritisCompletedClinicalTrials.gov
2H 2025Half-year disclosedempasiprubart (ARGX-117)ARGXTopline readout—ScheduledSEC 8-K Exhibit 99.1
2H 2025Half-year disclosedadimanebart (ARGX-119)ARGXTopline readout—ScheduledSEC 8-K Exhibit 99.1
June 30, 2025efgartigimod ivARGXPrimary completionGeneralized Myasthenia Gravis; gMG; Myasthenia Gravis, GeneralizedCompletedClinicalTrials.gov
April 10, 2025Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)ARGXLabel expansion—ApprovedopenFDA Drugs@FDA
April 10, 2025VYVGART (efgartigimod)ARGXPDUFA date—ApprovedSEC 8-K Exhibit 99.1
April 10, 2025VYVGART (efgartigimod)ARGXFDA approval—ApprovedSEC 8-K Exhibit 99.1
April 10, 2025Vyvgart (efgartigimod alfa)ARGXFDA approval—ApprovedSEC 8-K Exhibit 99.1
April 10, 2025—ARGXPDUFA date—ScheduledSEC 8-K Exhibit 99.1
1H 2025Half-year disclosedempasiprubart (ARGX-117)ARGXTrial start—ScheduledSEC 8-K Exhibit 99.1
August 8, 2024Vyvgart (efgartigimod alfa)ARGXLabel expansion—ApprovedopenFDA Drugs@FDA
August 8, 2024Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)ARGXLabel expansion—ApprovedopenFDA Drugs@FDA
June 21, 2024Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)ARGXLabel expansion—ApprovedopenFDA Drugs@FDA
June 21, 2024VYVGART (efgartigimod)ARGXFDA approval—ApprovedSEC 8-K Exhibit 99.1
Jul 2023Month disclosedVyvgart (efgartigimod alfa)ARGXTopline readout—PositiveSEC 8-K Exhibit 99.1
June 20, 2023Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)ARGXFDA approval—ApprovedopenFDA Drugs@FDA
March 22, 2022VYVGART (efgartigimod)ARGXTopline readoutgMGMet primary endpointSEC 8-K Exhibit 99.1
December 17, 2021Vyvgart (efgartigimod alfa)ARGXFDA approval—ApprovedopenFDA Drugs@FDA
Every catalyst is quoted from ARGX’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.